Search results
Showing 2701 to 2715 of 9071 results
Orforglipron for managing overweight and obesity in people 12 to 17 years
Awaiting development Reference number: GID-TA12451 Expected publication date: TBC
Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
Awaiting development Reference number: GID-TA12450 Expected publication date: TBC
Niraparib for treating newly diagnosed unmethylated glioblastoma
Awaiting development Reference number: GID-TA12449 Expected publication date: TBC
In development Reference number: GID-HTG10887 Expected publication date: 13 October 2026
Awaiting development Reference number: GID-TA12448 Expected publication date: TBC
Cagrilintide–semaglutide for managing overweight and obesity
Awaiting development Reference number: GID-TA12443 Expected publication date: TBC
Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression
Awaiting development Reference number: GID-TA12444 Expected publication date: TBC
In development Reference number: GID-HTG10902 Expected publication date: TBC
In development Reference number: GID-HTG10886 Expected publication date: 04 February 2027
Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over
Awaiting development Reference number: GID-TA12446 Expected publication date: TBC
In development Reference number: GID-NG10449 Expected publication date: 23 February 2027
Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)
Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Summary of the evidence on antimicrobial prescribing: delafloxacin
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis